We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Protein Panel Supports Monitoring of Treated Celiac Disease

By LabMedica International staff writers
Posted on 13 Oct 2026

Celiac disease is an autoimmune condition in which gluten triggers intestinal inflammation that can damage the gut and impair nutrient absorption. More...

Even with a gluten-free diet, some patients may continue to have underlying inflammation or intestinal injury that is not clearly reflected by current blood tests. 

The University of Oslo-led study evaluated targeted serum proteomics as a way to assess disease activity in celiac disease. Proteomics allows large numbers of proteins to be analyzed simultaneously in blood samples, and the researchers investigated whether circulating proteins could serve as biomarkers of intestinal inflammation, healing, and the extent of gut damage.

The study analyzed 264 blood and tissue samples from people with celiac disease, collected before treatment and after one year on a gluten-free diet. Samples from people without celiac disease were also examined. The samples were collected at Rikshospitalet between 2018 and 2024, with participants’ consent for research use.

The team identified 24 proteins associated with celiac disease. Nine proteins were particularly linked to the extent of intestinal damage and may indicate disease progression. People with untreated celiac disease had the highest levels of inflammatory proteins, while healthy individuals had the lowest. Protein levels also differed before and after treatment, suggesting that blood proteins may provide information about inflammation and healing in the gut.

The current blood test used in monitoring measures anti-tissue transglutaminase immunoglobulin A antibodies and total immunoglobulin A levels. The researchers stated that biomarker-based tests should not replace current methods, but could complement serology. The findings were published in Gastroenterology, with institutions including the University of Oslo, the Norwegian Coeliac Disease Research Centre, Oslo University Hospital, and Rikshospitalet.

“There is potential for tests based on these new biomarkers to be used alongside serology, which is the test used today and which does not distinguish clearly enough between ongoing intestinal damage and healing,” said Knut E.A. Lundin, MD, PhD, Professor of Medicine and Head of Clinical Education, Faculty of Medicine at the University of Oslo’s Faculty of Medicine.

Related Links
University of Oslo
Oslo University Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Image: Graphical Abstract (Nagy, G.R., Munkácsy, G., Murmu, A. et al. Beyond the linear genome: how reference bias threatens preventive medicine and geroscience. GeroScience, 2026. https://doi.org/10.1007/s11357-026-02436-z)

Study Shows How Genome Reference Bias Can Mislead Preventive Testing

Whole-genome sequencing is expected to play a growing role in preventive and predictive medicine, but accurate interpretation remains a major diagnostic challenge. The approach requires comparing billions... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.